PERSPECTIVE THERAPEUTICS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
PERSPECTIVE THERAPEUTICS, INC. (CATX) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations of $48.49 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2026-08-10
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $48.49M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $53.97M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $30.63M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $26.76M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations as first filed |
|---|---|---|
| 2026-06-30 | $48.49M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $53.97M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $30.63M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $26.76M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $28.85M 10-Q · filed 2026-08-10 | |
| 2025-03-31 | $44.41M 10-Q · filed 2026-05-11 | |
| 2024-12-31 | $61.58M 10-Q · filed 2026-08-10 | |
| 2024-09-30 | $226.44M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $252.19M 10-Q · filed 2025-08-13 | |
| 2024-03-31 | $142.30M 10-Q · filed 2025-05-12 | |
| 2023-12-31 | $9.42M 10-K · filed 2026-03-16 | |
| 2023-09-30 | $18.16M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $28.50M 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $36.63M 10-Q · filed 2024-05-15 | |
| 2022-12-31 | $21.18M 10-K/A · filed 2025-03-28 | |
| 2022-09-30 | $19.17M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $56.07M 10-K · filed 2024-03-28 | |
| 2022-03-31 | $59.09M 10-Q · filed 2023-05-15 | |
| 2021-12-31 | $60.54M 10-K · filed 2024-03-28 | $60.53M 10-Q · filed 2022-02-09 |
| 2021-09-30 | $61.87M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $64.01M 10-K · filed 2024-03-28 | |
| 2021-03-31 | $65.02M 10-Q · filed 2022-05-13 | |
| 2020-12-31 | $9.77M 10-Q · filed 2022-02-09 | |
| 2020-09-30 | $2.12M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $2.57M 10-KT · filed 2023-05-01 | |
| 2020-03-31 | $2.59M 10-Q · filed 2021-05-14 | |
| 2019-12-31 | $3.36M 10-Q · filed 2021-02-09 | |
| 2019-09-30 | $4.76M 10-Q · filed 2020-11-13 | |
| 2019-06-30 | $5.51M 10-KT · filed 2023-05-01 | |
| 2018-06-30 | $2.78M 10-K · filed 2021-09-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |